Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment.
Reperfusion injury is considered primarily an inflammatory response to oxidative stress. In vitro, oxygen free radicals induce the formation of oxidized phospholipids with platelet-activating factor (PAF) activity (PAF-like lipids). We examined the following: 1) whether PAF and PAF-like lipids are released during reperfusion; 2) the relationship between these phospholipids and oxidative damage on the one hand, and leukocyte recruitment in renal tissue on the other; and 3) whether antioxidant treatment influences the behavior of these phospholipids, the renal inflammatory response, and the outcome of postischemic acute renal failure. After 60 min of warm renal ischemia in rabbits, a release of PAF and, particularly, PAF-like lipids was seen in the first 15 min of reperfusion. In addition, the release of those phospholipids was associated with intense tissue DNA oxidation and with an increase in myeloperoxidase activity. Vitamin C was able to attenuate these postischemic oxidative changes, decrease PAF and PAF-like lipid levels, and, consequently, reduce myeloperoxidase activity. After 40 min of warm renal ischemia in rats, vitamin C treatment ameliorated renal function and structure. This is the first in vivo demonstration of the release of phospholipid oxidation products as part of an oxidative-inflammatory response after renal ischemia-reperfusion, with the release of phospholipid oxidation products significantly reduced by antioxidant treatment.
Lloberas
Núria
N
Laboratory of Experimental Nephrology, Department of Medicine, University of Barcelona, and Nephrology Service, Hospital Bellvitge, L'Hospitalet, Barcelona, Spain.
Torras
Juan
J
Herrero-Fresneda
Immaculate
I
Cruzado
Josep M
JM
Riera
Marta
M
Hurtado
Isabel
I
Grinyó
Josep M
JM
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001205:Ascorbic Acid / Q000494:pharmacology; D003404:Creatinine / Q000097:blood; D004249:DNA Damage; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000378:metabolism; D007249:Inflammation / Q000378:metabolism* / Q000503:physiopathology / Q000517:prevention & control; D007511:Ischemia / Q000503:physiopathology*; D007668:Kidney / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000187:drug effects / Q000378:metabolism*; D018384:Oxidative Stress / Q000502:physiology; D010972:Platelet Activating Factor / Q000187:drug effects / Q000378:metabolism*; D011817:Rabbits; D051381:Rats
D000975:Antioxidants; D008077:Lipoproteins, LDL; D010972:Platelet Activating Factor; C099252:oxidized low density lipoprotein; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003404:Creatinine; D003849:Deoxyguanosine; D001205:Ascorbic Acid